AECL
Yi Wang is a Research Scientist at Canadian Nuclear Laboratories since June 2014, focusing on investigations into low dose radiation induced cancer development. Additionally, Yi Wang serves as an Adjunct Professor at the University of Ottawa since June 2017 and has previously held a Postdoctoral Research Fellow position at the University of Toronto from February 2012 to May 2014, under the supervision of Sachdev Sidhu, Jason Moffat, and Brad Wouters, where the development of synthetic antibodies against hypoxia targets was a key research area. Prior postdoctoral work at the University of Toronto from January 2007 to December 2011, supervised by Dr. Michael Ohh, concentrated on the relationship between tumor hypoxia and the activation of receptor tyrosine kinases via endocytosis. Yi Wang holds a PhD in Cell Biology from the University of Alberta (2000-2006), a Master of Medicine in Pathology and Pathobiology from Tianjin Medical University (1997-2000), and a Bachelor of Medicine from the same institution (1992-1997).
AECL
1 followers
Atomic Energy of Canada Limited (AECL) is a federal Crown corporation responsible for the long-term, contractual arrangement with Canadian National Energy Alliance (CNEA) for the management and operation of Canadian Nuclear Laboratories (CNL) under a Government-owned, Contractor-operated (GoCo) model. This follows the announcement by the Government of Canada in June 2015 of the selection of CNEA through a competitive procurement process. AECL works to monitor performance under the GoCo arrangement to meet Government objectives. Under the GoCo model, AECL leverages its facilities, assets and intellectual property by bringing to bear private-sector rigour in the operation of the nuclear laboratories through the contract with CNEA, and fulfils its core mandate to: deliver on Canada’s radioactive waste and decommissioning responsibilities, provide nuclear expertise to support federal responsibilities, and offer services to users of the nuclear laboratories on commercial terms.